RU2010129295A - MEDICINAL PRODUCT FOR TREATING PROSTATE DISEASES AND METHOD FOR TREATING PROSTATE DISEASES - Google Patents

MEDICINAL PRODUCT FOR TREATING PROSTATE DISEASES AND METHOD FOR TREATING PROSTATE DISEASES Download PDF

Info

Publication number
RU2010129295A
RU2010129295A RU2010129295/15A RU2010129295A RU2010129295A RU 2010129295 A RU2010129295 A RU 2010129295A RU 2010129295/15 A RU2010129295/15 A RU 2010129295/15A RU 2010129295 A RU2010129295 A RU 2010129295A RU 2010129295 A RU2010129295 A RU 2010129295A
Authority
RU
Russia
Prior art keywords
antibodies
activated
aqueous
prostate
potentiated
Prior art date
Application number
RU2010129295/15A
Other languages
Russian (ru)
Other versions
RU2531049C2 (en
Inventor
Олег Ильич Эпштейн (RU)
Олег Ильич Эпштейн
Original Assignee
Олег Ильич Эпштейн (RU)
Олег Ильич Эпштейн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Олег Ильич Эпштейн (RU), Олег Ильич Эпштейн filed Critical Олег Ильич Эпштейн (RU)
Priority to RU2010129295/15A priority Critical patent/RU2531049C2/en
Priority to KR1020137003861A priority patent/KR20140014059A/en
Priority to SE1350184A priority patent/SE1350184A1/en
Priority to US13/135,898 priority patent/US20130064860A1/en
Priority to DE112011102358T priority patent/DE112011102358T5/en
Priority to AU2011278042A priority patent/AU2011278042B2/en
Priority to MYPI2013000108A priority patent/MY165267A/en
Priority to EA201300126A priority patent/EA030566B1/en
Priority to MX2013000547A priority patent/MX354187B/en
Priority to ES201390006A priority patent/ES2440393R1/en
Priority to SG2013002324A priority patent/SG187038A1/en
Priority to DE112011102350T priority patent/DE112011102350T5/en
Priority to PE2013000076A priority patent/PE20130398A1/en
Priority to NZ606767A priority patent/NZ606767A/en
Priority to CN2011800443324A priority patent/CN103108657A/en
Priority to NZ606775A priority patent/NZ606775A/en
Priority to AU2011278038A priority patent/AU2011278038B2/en
Priority to EP11775838.3A priority patent/EP2593140A2/en
Priority to EA201300129A priority patent/EA029860B1/en
Priority to EEP201300006A priority patent/EE201300006A/en
Priority to SG10201505564VA priority patent/SG10201505564VA/en
Priority to CZ20130105A priority patent/CZ2013105A3/en
Priority to IT000631A priority patent/ITTO20110631A1/en
Priority to SG2013002308A priority patent/SG187036A1/en
Priority to PCT/IB2011/002350 priority patent/WO2012007845A2/en
Priority to SG10201505561TA priority patent/SG10201505561TA/en
Priority to JP2013519179A priority patent/JP2013538791A/en
Priority to MX2013000543A priority patent/MX2013000543A/en
Priority to CA2804966A priority patent/CA2804966A1/en
Priority to PCT/IB2011/002417 priority patent/WO2012007849A2/en
Priority to FR1156482A priority patent/FR2962656A1/en
Priority to GB1302649.7A priority patent/GB2495884B/en
Priority to US13/135,901 priority patent/US9308275B2/en
Priority to FR1156476A priority patent/FR2962655A1/en
Priority to IT000639A priority patent/ITTO20110639A1/en
Priority to CN201180044500XA priority patent/CN103282384A/en
Priority to GB1302651.3A priority patent/GB2495885B/en
Priority to JP2013519175A priority patent/JP2013538186A/en
Priority to EP11784771.5A priority patent/EP2593483A2/en
Priority to BR112013000840A priority patent/BR112013000840A2/en
Priority to ES201390004A priority patent/ES2425314R1/en
Priority to CA2805094A priority patent/CA2805094A1/en
Priority to ARP110102578A priority patent/AR082247A1/en
Publication of RU2010129295A publication Critical patent/RU2010129295A/en
Priority to CL2013000099A priority patent/CL2013000099A1/en
Priority to NO20130222A priority patent/NO20130222A1/en
Priority to LT2013016A priority patent/LT5988B/en
Priority to DKPA201370079A priority patent/DK201370079A/en
Priority to FI20135143A priority patent/FI20135143L/en
Application granted granted Critical
Publication of RU2531049C2 publication Critical patent/RU2531049C2/en
Priority to US15/060,202 priority patent/US20160251448A1/en
Priority to US15/060,157 priority patent/US20160244531A1/en
Priority to JP2016131664A priority patent/JP2016199570A/en
Priority to JP2016135750A priority patent/JP2016216483A/en
Priority to JP2018085388A priority patent/JP2018150322A/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

1. Лекарственное средство для лечения заболеваний предстательной железы, содержащее активированную-потенцированную форму антител к простатоспецифическому антигену, отличающееся тем, что выполнено в виде фармацевтической композиции и содержит в качестве дополнительного усиливающего компонента активированную-потенцированную форму антител к эндотелиальной NO-синтазе. ! 2. Лекарственное средство по п.1, отличающееся тем, что активированную-потенцированную форму антител к простатоспецифическому антигену и активированную-потенцированную форму антител к эндотелиальной NO-синтазе используют в виде активированного-потенцированного водного или водно-спиртового раствора, полученного в процессе последовательного многократного разведения матричного раствора соответствующих антител в водном или водно-спиртовом растворителе и промежуточного внешнего механического воздействия - вертикального встряхивания. ! 3. Лекарственное средство по п.1 или 2, отличающееся тем, что фармацевтическая композиция выполнена в твердой лекарственной форме и содержит эффективное количество гранул нейтрального носителя, насыщенного смесью активированной-потенцированной формы антител к простатоспецифическому антигену и активированной-потенцированной формы антител к эндотелиальной NO-синтазе, и фармацевтически приемлемые добавки. !4. Лекарственное средство по п.1 или 2, отличающееся тем, что водные или водно-спиртовые растворы гомеопатически активированных-потенцированных форм антител к простатоспецифическому антигену и к эндотелиальной NO-синтазе получены путем многократного последовательного разведения и промежуточного вн 1. A drug for the treatment of prostate diseases, containing an activated-potentiated form of antibodies to a prostate-specific antigen, characterized in that it is made in the form of a pharmaceutical composition and contains, as an additional reinforcing component, an activated-potentiated form of antibodies to endothelial NO synthase. ! 2. The drug according to claim 1, characterized in that the activated-potentiated form of antibodies to the prostate-specific antigen and the activated-potentiated form of antibodies to endothelial NO synthase are used in the form of an activated-potentiated aqueous or aqueous-alcoholic solution obtained in a multiple sequential process dilution of the matrix solution of the corresponding antibodies in an aqueous or aqueous-alcoholic solvent and an intermediate external mechanical action - vertical shaking. ! 3. The drug according to claim 1 or 2, characterized in that the pharmaceutical composition is made in solid dosage form and contains an effective amount of granules of a neutral carrier saturated with a mixture of an activated-potentiated form of antibodies to a prostate-specific antigen and an activated-potentiated form of antibodies to endothelial NO- synthase, and pharmaceutically acceptable additives. !four. The drug according to claim 1 or 2, characterized in that the aqueous or aqueous-alcoholic solutions of homeopathically activated-potentiated forms of antibodies to the prostate-specific antigen and to endothelial NO synthase are obtained by repeated serial dilution and intermediate

Claims (9)

1. Лекарственное средство для лечения заболеваний предстательной железы, содержащее активированную-потенцированную форму антител к простатоспецифическому антигену, отличающееся тем, что выполнено в виде фармацевтической композиции и содержит в качестве дополнительного усиливающего компонента активированную-потенцированную форму антител к эндотелиальной NO-синтазе.1. A drug for the treatment of prostate diseases, containing an activated-potentiated form of antibodies to a prostate-specific antigen, characterized in that it is made in the form of a pharmaceutical composition and contains, as an additional reinforcing component, an activated-potentiated form of antibodies to endothelial NO synthase. 2. Лекарственное средство по п.1, отличающееся тем, что активированную-потенцированную форму антител к простатоспецифическому антигену и активированную-потенцированную форму антител к эндотелиальной NO-синтазе используют в виде активированного-потенцированного водного или водно-спиртового раствора, полученного в процессе последовательного многократного разведения матричного раствора соответствующих антител в водном или водно-спиртовом растворителе и промежуточного внешнего механического воздействия - вертикального встряхивания.2. The drug according to claim 1, characterized in that the activated-potentiated form of antibodies to the prostate-specific antigen and the activated-potentiated form of antibodies to endothelial NO synthase are used in the form of an activated-potentiated aqueous or aqueous-alcoholic solution obtained in a multiple sequential process dilution of the matrix solution of the corresponding antibodies in an aqueous or aqueous-alcoholic solvent and an intermediate external mechanical action - vertical shaking. 3. Лекарственное средство по п.1 или 2, отличающееся тем, что фармацевтическая композиция выполнена в твердой лекарственной форме и содержит эффективное количество гранул нейтрального носителя, насыщенного смесью активированной-потенцированной формы антител к простатоспецифическому антигену и активированной-потенцированной формы антител к эндотелиальной NO-синтазе, и фармацевтически приемлемые добавки.3. The drug according to claim 1 or 2, characterized in that the pharmaceutical composition is made in solid dosage form and contains an effective amount of granules of a neutral carrier saturated with a mixture of an activated-potentiated form of antibodies to a prostate-specific antigen and an activated-potentiated form of antibodies to endothelial NO- synthase, and pharmaceutically acceptable additives. 4. Лекарственное средство по п.1 или 2, отличающееся тем, что водные или водно-спиртовые растворы гомеопатически активированных-потенцированных форм антител к простатоспецифическому антигену и к эндотелиальной NO-синтазе получены путем многократного последовательного разведения и промежуточного внешнего воздействия из матричных растворов аффинно очищенных антител к простатоспецифическому антигену и к эндотелиальной NO-синтазе с концентрацией 0,5÷5,0 мг/мл.4. The drug according to claim 1 or 2, characterized in that the aqueous or aqueous-alcoholic solutions of homeopathically activated-potentiated forms of antibodies to the prostate-specific antigen and to endothelial NO synthase are obtained by repeated serial dilution and intermediate external exposure from affinity purified matrix solutions antibodies to prostate-specific antigen and to endothelial NO synthase with a concentration of 0.5 ÷ 5.0 mg / ml 5. Лекарственное средство по п.1 или 2, отличающееся тем, что каждый из компонентов сверхмалых доз аффинно очищенных антител используют в виде смеси различных, преимущественно сотенных, гомеопатических разведений.5. The drug according to claim 1 or 2, characterized in that each of the components of the ultra-low doses of affinity purified antibodies is used as a mixture of various, mainly hundred, homeopathic dilutions. 6. Лекарственное средство по п.3, характеризующееся тем, что фармацевтически приемлемые добавки включают лактозу, целлюлозу микрокристаллическую и магния стеарат.6. The drug according to claim 3, characterized in that the pharmaceutically acceptable additives include lactose, microcrystalline cellulose and magnesium stearate. 7. Способ лечения заболеваний предстательной железы путем введения в организм активированной-потенцированной формы антител к простатоспецифическому антигену, характеризующийся тем, что дополнительно одновременно сочетано вводят активированную-потенцированную форму сверхмалых доз аффинно очищенных антител к эндотелиальной NO-синтазе.7. A method of treating prostate diseases by introducing into the body an activated-potentiated form of antibodies to a prostate-specific antigen, characterized in that an activated-potentiated form of ultra-low doses of affinity-purified antibodies to endothelial NO synthase is additionally combined at the same time. 8. Способ по п.7, характеризующийся тем, что активированную-потенцированную форму антител к простатоспецифическому антигену и активированную-потенцированную форму антител к эндотелиальной NO- синтазе используют в виде активированного-потенцированного водного или водно-спиртового раствора каждого компонента, полученного в процессе последовательного многократного разведения в водном или водно-спиртовом растворителе и промежуточного внешнего механического воздействия - вертикального встряхивания.8. The method according to claim 7, characterized in that the activated-potentiated form of antibodies to the prostate-specific antigen and the activated-potentiated form of antibodies to endothelial NO synthase are used in the form of an activated-potentiated aqueous or aqueous-alcoholic solution of each component obtained in the sequential multiple dilutions in an aqueous or aqueous-alcoholic solvent and an intermediate external mechanical action - vertical shaking. 9. Способ лечения по п.7, характеризующийся тем, что используют приготовленные в виде единого лекарственного препарата - одной лекарственной формы - смесь различных гомеопатических разведений антител к простатоспецифическому антигену в сочетании со смесью различных гомеопатических разведений антител к эндотелиальной NO-синтазе. 9. The treatment method according to claim 7, characterized in that they use a mixture of different homeopathic dilutions of antibodies to a prostate-specific antigen in combination with a mixture of different homeopathic dilutions of antibodies to endothelial NO synthase, prepared as a single drug.
RU2010129295/15A 2010-07-15 2010-07-15 Therapeutic agent for treating prostatic diseases and method of treating prostatic diseases RU2531049C2 (en)

Priority Applications (53)

Application Number Priority Date Filing Date Title
RU2010129295/15A RU2531049C2 (en) 2010-07-15 2010-07-15 Therapeutic agent for treating prostatic diseases and method of treating prostatic diseases
KR1020137003861A KR20140014059A (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
SE1350184A SE1350184A1 (en) 2010-07-15 2011-07-15 PROCEDURE TO INCREASE THE EFFECT OF AN ACTIVATED, POTENTIZED FORM OF AN ANTIBODY
US13/135,898 US20130064860A1 (en) 2010-07-15 2011-07-15 Combination pharmaceutical composition and methods of theating genitourinary system disorders
DE112011102358T DE112011102358T5 (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
AU2011278042A AU2011278042B2 (en) 2010-07-15 2011-07-15 Combination pharmaceutical composition and methods of treating genitourinary system disorders
MYPI2013000108A MY165267A (en) 2010-07-15 2011-07-15 Combination pharmaceutical composition and methods of treating genitourinary system disorders
EA201300126A EA030566B1 (en) 2010-07-15 2011-07-15 Method of increasing therapeutic effectiveness of an activated-potentiated form of an antibody to an endogenous biological molecule and pharmaceutical composition
MX2013000547A MX354187B (en) 2010-07-15 2011-07-15 Combination pharmaceutical composition and methods of treating genitourinary system disorders.
ES201390006A ES2440393R1 (en) 2010-07-15 2011-07-15 A METHOD FOR INCREASING THE EFFECT OF A POTENTIATED ACTIVATED FORM OF AN ANTIBODY
SG2013002324A SG187038A1 (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
DE112011102350T DE112011102350T5 (en) 2010-07-15 2011-07-15 A combination pharmaceutical composition and method for treating disorders of the genitourinary system
PE2013000076A PE20130398A1 (en) 2010-07-15 2011-07-15 A METHOD TO INCREASE THE EFFECT OF AN ACTIVE ENHANCED FORM OF AN ANTIBODY
NZ606767A NZ606767A (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
CN2011800443324A CN103108657A (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
NZ606775A NZ606775A (en) 2010-07-15 2011-07-15 Combination pharmaceutical composition and methods of treating genitourinary system disorders
AU2011278038A AU2011278038B2 (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
EP11775838.3A EP2593140A2 (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
EA201300129A EA029860B1 (en) 2010-07-15 2011-07-15 Pharmaceutical composition and methods of treating genitourinary system disorders
EEP201300006A EE201300006A (en) 2010-07-15 2011-07-15 A pharmaceutical composition for enhancing the effect of an activated and potentiated form of an antibody
SG10201505564VA SG10201505564VA (en) 2010-07-15 2011-07-15 Combination pharmaceutical composition and methods of treating genitourinary system disorders
CZ20130105A CZ2013105A3 (en) 2010-07-15 2011-07-15 Method of increasing effect of antibody activated potentiated form
IT000631A ITTO20110631A1 (en) 2010-07-15 2011-07-15 PHARMACEUTICAL COMPOSITION OF COMBINATION AND METHODS TO TREAT GENITOURINARY SYSTEM DISEASES
SG2013002308A SG187036A1 (en) 2010-07-15 2011-07-15 Combination pharmaceutical composition and methods of treating genitourinary system disorders
PCT/IB2011/002350 WO2012007845A2 (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
SG10201505561TA SG10201505561TA (en) 2010-07-15 2011-07-15 A Method Of Increasing The Effect Of An Activated-Potentiated Form Of An Antibody
JP2013519179A JP2013538791A (en) 2010-07-15 2011-07-15 Combination pharmaceutical composition and method for treating genitourinary disorders
MX2013000543A MX2013000543A (en) 2010-07-15 2011-07-15 Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract.
CA2804966A CA2804966A1 (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
PCT/IB2011/002417 WO2012007849A2 (en) 2010-07-15 2011-07-15 Combination pharmaceutical composition and methods of treating genitourinary system disorders
FR1156482A FR2962656A1 (en) 2010-07-15 2011-07-15 METHOD FOR INCREASING THE EFFECT OF AN ACTIVATED-POTENTIALIZED FORM OF ANTIBODY
GB1302649.7A GB2495884B (en) 2010-07-15 2011-07-15 A method of increasing the effect of an activated-potentiated form of an antibody
US13/135,901 US9308275B2 (en) 2010-07-15 2011-07-15 Method of increasing the effect of an activated-potentiated form of an antibody
FR1156476A FR2962655A1 (en) 2010-07-15 2011-07-15 PHARMACEUTICAL ASSOCIATION COMPOSITION AND USES THEREOF IN METHODS OF TREATMENT OF GENITAL URINARY SYSTEM DISORDERS
IT000639A ITTO20110639A1 (en) 2010-07-15 2011-07-15 METHOD TO INCREASE THE EFFECT OF AN ACTIVE-ENHANCED SHAPE OF AN ANTI-BODY
CN201180044500XA CN103282384A (en) 2010-07-15 2011-07-15 Combination pharmaceutical composition and methods of treating genitourinary system disorders
GB1302651.3A GB2495885B (en) 2010-07-15 2011-07-15 Combination pharmaceutical composition and methods of treating genitourinary system disorders
JP2013519175A JP2013538186A (en) 2010-07-15 2011-07-15 Method for increasing the effect of activation-enhancing antibodies
EP11784771.5A EP2593483A2 (en) 2010-07-15 2011-07-15 Combination pharmaceutical composition and methods of treating genitourinary system disorders
BR112013000840A BR112013000840A2 (en) 2010-07-15 2011-07-15 method for enhancing the effect of potentiated activated form of antibody to biological endogenous molecule, pharmaceutical composition and use of combination of endogenous biological molecule with potentiated activated form of antibody to endothelial synthase.
ES201390004A ES2425314R1 (en) 2010-07-15 2011-07-15 Combined pharmaceutical composition and use to prepare medicines for the treatment of disorders of the genitourinary system
CA2805094A CA2805094A1 (en) 2010-07-15 2011-07-15 Combination pharmaceutical composition and methods of treating genitourinary system disorders
ARP110102578A AR082247A1 (en) 2010-07-15 2011-07-18 A METHOD FOR INCREASING THE EFFECTS OF A POTENTIATED ACTIVATED FORM OF AN ANTIBODY
CL2013000099A CL2013000099A1 (en) 2010-07-15 2013-01-10 A method of increasing the effect of an potentiated active form of an antibody to an endogenous biological molecule, comprising the combination of the endogenous biological molecule with an enhanced active form of an endoltelial non-synthase antibody; composition that understands it.
NO20130222A NO20130222A1 (en) 2010-07-15 2013-02-08 Process for increasing the effect of an activated-potentiated form of an antibody
LT2013016A LT5988B (en) 2010-07-15 2013-02-14 A method of increasing the effect of an activated-potentiated form of an antibody
DKPA201370079A DK201370079A (en) 2010-07-15 2013-02-14 A method of increasing the effect of an activated-potentiated form of an antibody
FI20135143A FI20135143L (en) 2010-07-15 2013-02-15 A method of increasing the potency of an activated potentiated form of an antibody
US15/060,202 US20160251448A1 (en) 2010-07-15 2016-03-03 Method of increasing the effect of an activated-potentiated form of an antibody
US15/060,157 US20160244531A1 (en) 2010-07-15 2016-03-03 Method of increasing the effect of an activated-potentiated form of an antibody
JP2016131664A JP2016199570A (en) 2010-07-15 2016-07-01 Combination pharmaceutical composition and methods of treating genitourinary system disorders
JP2016135750A JP2016216483A (en) 2010-07-15 2016-07-08 Method of increasing effect of activated-potentiated antibody
JP2018085388A JP2018150322A (en) 2010-07-15 2018-04-26 Combined pharmaceutical composition, and method for treating urogenital system disorder

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2010129295/15A RU2531049C2 (en) 2010-07-15 2010-07-15 Therapeutic agent for treating prostatic diseases and method of treating prostatic diseases

Publications (2)

Publication Number Publication Date
RU2010129295A true RU2010129295A (en) 2012-01-20
RU2531049C2 RU2531049C2 (en) 2014-10-20

Family

ID=45785351

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010129295/15A RU2531049C2 (en) 2010-07-15 2010-07-15 Therapeutic agent for treating prostatic diseases and method of treating prostatic diseases

Country Status (1)

Country Link
RU (1) RU2531049C2 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997005901A1 (en) * 1995-08-03 1997-02-20 Sinha Akhouri A Targeting of organs by immunoconjugates
RU2192889C1 (en) * 2001-03-16 2002-11-20 Эпштейн Олег Ильич Medicinal preparation and method for treating prostatic diseases

Also Published As

Publication number Publication date
RU2531049C2 (en) 2014-10-20

Similar Documents

Publication Publication Date Title
RU2011127052A (en) METHOD FOR TREATING THE HEAD-VARIABLE OF VARIOUS GENESIS, KINETOSIS AND VEGETOVASCULAR DYSTONIA (OPTIONS) AND MEDICINAL PRODUCT
RU2011127059A (en) NEUROTROPIC MEDICINE AND METHOD OF TREATMENT OF ORGANIC DISEASES OF THE NERVOUS SYSTEM, PSYCHOORGANIC SYNDROME AND ENCEPHALOPATHY OF VARIOUS GENESIS
RU2010133053A (en) INTEGRATED MEDICINE FOR TREATMENT OF VIRAL DISEASES AND METHOD OF TREATMENT OF VIRAL DISEASES
RU2010129295A (en) MEDICINAL PRODUCT FOR TREATING PROSTATE DISEASES AND METHOD FOR TREATING PROSTATE DISEASES
RU2011127058A (en) MEDICINE FOR TREATMENT OF ALZHEIMER'S DISEASE AND METHOD OF TREATMENT OF ALZHEIMER'S DISEASE
RU2010130353A (en) MEDICINE FOR TREATMENT OF ALZHEIMER'S DISEASE AND METHOD OF TREATMENT OF ALZHEIMER'S DISEASE
RU2010129294A (en) MEDICINE FOR TREATMENT OF ERECTILE DYSFUNCTIONS AND METHOD OF TREATMENT OF ERECTILE DYSFUNCTIONS
RU2010130358A (en) MEDICINE FOR TREATMENT OF ATTENTION DEFICIENCY SYNDROME AND METHOD FOR TREATMENT OF ATTENTION DEFICIENCY SYNDROME
RU2010130355A (en) MEDICINAL PRODUCT AND METHOD FOR TREATMENT OF ORGANIC DISEASES OF THE NERVOUS SYSTEM, PSYCHOORGANIC SYNDROME AND ENCEPHALOPATHY OF VARIOUS GENESIS
RU2010130356A (en) MEDICINAL PRODUCT AND METHOD FOR TREATMENT OF VEGETO-VASCULAR DYSTONIA, VERTAIN SYNDROME OF VARIOUS GENESIS AND KINETOSIS
RU2011134414A (en) FULVIC ACID COMBINATION FOR TREATMENT OF VARIOUS CONDITIONS AND DISEASES
RU2011127055A (en) MEDICINAL PRODUCT FOR TREATMENT OF NEUROLOGICAL-BEHAVIORAL DEVELOPMENT DISORDERS AND METHOD OF TREATMENT OF NEUROLOGICAL-BEHAVIORAL DISORDERS OF DEVELOPMENT
RU2010130350A (en) METHOD FOR TREATING DEPENDENCE ON PSYCHOACTIVE SUBSTANCES, ALCOHOLISM AND TOBACCO SMOKING AND MEDICINAL PRODUCT FOR TREATING DEPENDENCE ON PSYCHOACTIVE SUBSTANCES, ALCOHOLISM AND TOBACCO SMOKING
RU2011124809A (en) MEDICINE FOR TREATMENT OF PATHOLOGICAL SYNDROME AND METHOD FOR TREATING FUNCTIONAL INTESTINAL DISORDERS
RU2013154072A (en) MEDICINE FOR TREATMENT OF KINETOSIS AND METHOD OF TREATMENT OF KINETOSIS
RU2010131387A (en) MEDICINE FOR TREATMENT OF MULTIPLE SCLEROSIS AND METHOD OF TREATMENT OF MULTIPLE SCLEROSIS
RU2013154073A (en) PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING A PATHOLOGICAL SYNDROME
RU2013154070A (en) METHOD FOR TREATMENT OF VEGETAIN-VASCULAR DISTONIA AND MEDICINAL PRODUCT
RU2013152871A (en) DIABETES TREATMENT METHOD AND COMBINED MEDICINE
RU2010129293A (en) MEDICINE FOR TREATMENT OF FUNCTIONAL DISORDERS OF THE GASTROINTESTINAL TRACT AND METHOD OF TREATMENT OF FUNCTIONAL DISORDERS OF THE GASTROINTESTINAL TRACT
RU2011127056A (en) MEDICINAL PRODUCT FOR TREATMENT OF PATHOLOGICAL SYNDROME AND METHOD FOR TREATING MULTIPLE SCLEROSIS
RU2013154071A (en) MEDICINAL PRODUCT AND METHOD FOR TREATMENT OF HEAD-WAYS
RU2010131386A (en) MEDICINAL PRODUCT FOR TREATMENT OF INFECTIOUS DISEASES ASSOCIATED WITH NEUROTOXIC DISORDERS, AND METHOD FOR TREATMENT OF INFECTIOUS DISEASES ASSOCIATED WITH NEUROTOXIC DISEASES
RU2010129297A (en) MEDICINAL PRODUCT FOR TREATMENT OF INFECTIOUS DISEASES ASSOCIATED WITH NEUROTOXIC DISORDERS, AND METHOD FOR TREATMENT OF INFECTIOUS DISEASES ASSOCIATED WITH NEUROTOXIC DISEASES
RU2010129292A (en) METHOD FOR TREATING VEGETAIN VASCULAR DISTONIA AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF VEGETAIN VASCULAR DISTONIA

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant
QZ41 Official registration of changes to a registered agreement (patent)

Free format text: LICENCE FORMERLY AGREED ON 20130114

Effective date: 20160229

QZ41 Official registration of changes to a registered agreement (patent)

Free format text: LICENCE FORMERLY AGREED ON 20130114

Effective date: 20170830

QC41 Official registration of the termination of the licence agreement or other agreements on the disposal of an exclusive right

Free format text: LICENCE FORMERLY AGREED ON 20130114

Effective date: 20190129

PC41 Official registration of the transfer of exclusive right

Effective date: 20190201